Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASES OF THE WEEK
Apple Inc. v. Qualcomm Inc., Appeal Nos. 2020-1683, -1763, -1764, 1827 (Fed. Cir. Nov. 10, 2021)
Our Case of the Week reinforces a developing body of law concerning standing to appeal from an adverse PTAB decision in an IPR. This is the second such decision arising from a global settlement between Apple and Qualcomm this year. We wrote about the first case, in April this year, here. As with that case, the Federal Circuit affirmed that Apple has no standing to appeal adverse IPR decisions.
Qualcomm sued Apple for infringement of a number of patents. Apple filed petitions for IPR at the Patent Office. In 2019, the parties settled their disputes pursuant to a six-year global patent license agreement with a two-year extension option. That resulted in dismissal of the case with prejudice. Ultimately, the PTAB found that Apple had failed to prove various claims unpatentable.
By Nika Aldrich
ALSO THIS WEEK
ROHM Semiconductor USA, LLC v. MaxPower Semiconductor, Inc., Appeal No. 2021-1709 (Fed. Cir. Nov. 12, 2021)
In an appeal from the United States District Court for the Northern District of California, the Federal Circuit addressed whether the district court erred in holding that the parties agreed to arbitrate whether a patent dispute fit within the arbitrability clause in an agreement. Applying Ninth Circuit law, the Federal Circuit affirmed the district court’s ruling, holding that the parties clearly and unmistakably delegated authority to the arbitrator to arbitrate arbitrability. In doing so, the Federal Circuit re-affirmed the near universal principle that in contracts between sophisticated parties, incorporation of rules with a provision on the subject is normally sufficient “clear and unmistakable” evidence of the parties’ intent to delegate the question of arbitrability to an arbitrator.
A copy of the opinion can be found here.
Edited by: Scott D. Eads and Nika Aldrich, Schwabe Williamson & Wyatt
Contributor: Mario Delegato
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…